Siren LLC’s Amylyx Pharmaceuticals AMLX Stock Holding History

Siren LLC’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.6M	Buy	1,480,586 +250,586	+20%	+$3.88M	0.54%	48
2026 Q1	$17.1M	Buy	+1,230,000	New	+$17.3M	0.47%	45

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Siren LLC's AMLX Position: Q2 2026 in Review

Siren LLC increased its Amylyx Pharmaceuticals (AMLX) stake by 20% in Q2 2026, buying an estimated $3.88M and bringing the position to 1,480,586 shares worth $26.6M. The position accounts for 0.54% of the portfolio, ranked #48.

Siren LLC first reported a position in AMLX in Q1 2026 and has held it in 2 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Siren LLC held 1,480,586 shares of Amylyx Pharmaceuticals worth $26.6M as of Q2 2026.
Siren LLC bought 250,586 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $3.88M.
Amylyx Pharmaceuticals made up 0.54% of Siren LLC's portfolio in Q2 2026, its #48 holding.
Siren LLC first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.